Ryan Allway July 21st, 2021 Psychedelics Training program established ahead of Phase II clinical trials Phase IIa due to start imminently and Phase IIb expected to commence in 2022 LONDON, July 21, 2021 /PRNewswire/ — Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma“), a neuropharmaceutical company focused on psychedelic-assisted... Read more
